upadacitinib oral
Selected indexed studies
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (N Engl J Med, 2023) [PMID:37224198]
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (JAMA Dermatol, 2021) [PMID:34347860]
- Treatment of Oral Erosive Lichen Planus With Upadacitinib. (JAMA Dermatol, 2022) [PMID:35294521]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. (2020) pubmed
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. (2023) pubmed
- Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. (2021) pubmed
- Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. (2021) pubmed
- Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. (2022) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. (2021) pubmed
- Treatment of Oral Erosive Lichen Planus With Upadacitinib. (2022) pubmed
- Oral tofacitinib, baricitinib and upadacitinib monotherapy for steroid-resistant vitiligo: A prospective case series. (2025) pubmed
- Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease: A Post Hoc Analysis of 3 Phase 3 Trials. (2025) pubmed